Mastering ATTR-CM

Prevalence studies and meta-analyses

1. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies

2. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis

Guidelines and position statements

1. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

Deep Dive

1. A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction

2. Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis

3. Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis

4. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy

Tafamidis – Clinical trials and updates

1. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-ACT Study)

2. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (LTE Study)

3. Improvements in Efficacy Measures With Tafamidis in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial

4. Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study